McKesson’s latest deal carries a $5.8 billion headline, but its own proposed investment is about $1.4 billion. Naturally, I wanted to know how those numbers fit together. One is the enterprise value of the business; the other buys McKesson a minority equity stake.
On October 6, McKesson and private-equity firm Clayton, Dubilier & Rice announced an agreement to buy Option Care Health for $32.05 per share in cash, valuing the business at approximately $5.8 billion including debt. McKesson would invest about $1.4 billion for a roughly 49% interest. CD&R would hold approximately 51%.
Those numbers describe different things. The distinction matters to anyone trying to work out what McKesson shareholders would actually own, how the investment would appear in earnings, and which risks would come along for the ride.
A minority stake with a very specific accounting plan
Option Care provides infusion services in patients’ homes and other treatment sites. McKesson says the investment fits its push into specialty care and community-based treatment. That explains the strategic appeal. It doesn’t settle the investment return.
The detail that caught my eye is how McKesson intends to report the stake after closing: equity-method accounting, with its share of Option Care’s net income or loss recorded in “Other Income, net.” Option Care would remain a separate company with its own management.
So I wouldn’t take Option Care’s sales and simply paste them onto McKesson’s revenue forecast. Under the disclosed plan, the earnings contribution is the place to look. A large business can become an important investment without its entire sales total becoming the investor’s reported revenue.
That gives us a useful follow-up question for McKesson’s future reports: what contribution is this investment producing, and what costs or adjustments sit around it? Our guide to reading an earnings report explains why the headline profit number deserves that extra look.
The financing deserves its own chair at the table
The $5.8 billion figure is enterprise value. McKesson’s $1.4 billion is its proposed equity investment. Dividing one by the other won’t tell us McKesson’s ownership percentage. The announcement already gives that figure: about 49%.
For the broader funding picture, the October 6 regulatory filing identifies approximately $2.873 billion in combined equity commitments from CD&R’s fund and McKesson. It also describes commitments for up to $3.15 billion in debt financing, including repayment of existing debt, and up to $500 million in revolving credit. Part of the revolver may help fund the transaction.
These are financing commitments, not a statement that every available dollar has been borrowed. Nor should we add the maximum amounts together and call the answer the purchase price. The funding package covers more than the cash going to existing shareholders.
The agreement says closing isn’t conditional on the buyer obtaining financing. The financing commitments still have conditions, and Option Care’s ability to force equity funding and closing is limited. Among other requirements, the debt financing must have been funded or be available at closing, subject only to the equity funding.
For McKesson investors, the smaller equity investment also doesn’t make the underlying financing irrelevant. Debt costs and operating performance can affect the earnings available to the owners. I’d want to understand those economics before celebrating the size of the stake.
Option Care shareholders still have a wait
The companies expect to close in the first half of calendar 2027, subject to shareholder and regulatory approvals and other conditions. The $32.05 cash payment belongs to a completed transaction. It isn’t money arriving in shareholders’ accounts today. Option Care would become privately held and leave Nasdaq upon completion.
Option Care is also withdrawing its previously disclosed financial guidance following the announcement. It plans to report third-quarter results on November 4 without a live earnings call. I wouldn’t read that withdrawal alone as evidence that operations have worsened; the company ties the decision to the transaction.
The possible next deal can wait its turn
The agreement establishes a framework for McKesson eventually buying CD&R’s interest, subject to specified conditions and regulatory approvals. That’s interesting, but I’m keeping the future possibility in a separate mental folder. Today’s announced investment is a minority stake.
For McKesson shareholders, I’d focus on what the roughly $1.4 billion stake contributes to earnings, including the effect of financing costs. I’ll be looking to the merger proxy and future McKesson disclosures for more detail on those economics.
For general education. This analysis is not personalized investment advice.